U.S. Patent Case Study 2026: Markush Claim Drafting Rules, Improper Group Rejections & Federal Circuit Infringement Dispute Standards

Administered by the USPTO and standardized in MPEP §2117, Markush claims are the

primary generic claim framework for chemical, pharmaceutical, battery and material

science inventions, allowing applicants to list alternative substituents, raw materials or

structural components with the format “selected from the group consisting of”. Valid

Markush groupings must satisfy two core statutory-judicial thresholds: shared core structural

feature and unified common technical utility, per the landmark In re Harnisch precedent.

Cross-border chemical and biotech R&D teams routinely face full claim rejections, PTAB

appeal losses and post-grant infringement defeats due to overbroad mixed-category

Markush groups, ambiguous transitional wording (“consisting of” vs “comprising”),

and insufficient specification support for alternative species. This case analyzes a Federal

Circuit pharmaceutical infringement reversal rooted in defective Markush drafting,

unpacks examination rejection logic, and delivers standardized claim drafting compliance

rules for global chemistry and life sciences applicants.

Case Overview

A Swiss biopharmaceutical developer filed a U.S. utility patent for sustained-release

oral inflammatory bowel disease drugs in 2022, drafting independent claims with a

broad Markush matrix defining matrix-forming excipients as “selected from inorganic

metal salts, aromatic carboxylic acids, aliphatic amides, triazine heterocycles and natural

plant waxes” without unifying core structural or functional characteristics in the specification.

During substantive examination, the USPTO examiner issued an improper Markush grouping

rejection under MPEP 2117, holding the five categories lacked a shared essential structural

moiety and exhibited divergent release-modulating effects. The applicant amended only minor

substituent ranges without splitting the mixed chemical-class group, then appealed to the

PTAB, which sustained the rejection. To expedite market launch, the firm split the original

single Markush into three narrow dependent claims and secured allowance for limited

species. Years later, a U.S. generic drug manufacturer filed an ANDA and launched a competing

tablet formulation using a heterocyclic triazine excipient excluded from the narrowed allowed

Markush scope. The patentee filed district court infringement litigation, arguing the original

broad inventive concept covered the generic’s triazine component. The Federal Circuit

reversed the lower court’s infringement judgment in 2025, ruling the PTAB’s Markush

restriction during prosecution created a clear prosecution history estoppel bar: the applicant

surrendered broad multi-class coverage to obtain patent allowance, and the triazine raw material

fell outside the enforceable scope of the final amended Markush limitations. The Swiss enterprise

lost all infringement remedies against the generic competitor, suffering massive U.S. market share

erosion after hundreds of thousands in prosecution and litigation expenses.Core Legal & Procedural

Insights

● First, dual mandatory criteria define a proper Markush group (In re Harnisch): all alternative

species within the grouping must (1) possess a single identical core structural feature that delivers

the invention’s technical effect, and (2) share a unified common industrial/technical utility directly

derived from that core structure. Mixing inorganic salts, aromatic acids and heterocyclic rings with no

shared backbone automatically triggers an improper group rejection, a merits-based objection

appealable to the PTAB. Pure functional similarity without matching core chemical architecture cannot

cure defective grouping. Second, transitional phrase wording creates rigid closed/open scope divides

critical for infringement:“Consisting of” establishes a closed Markush group, excluding any unlisted

components or mixed blends, as confirmed in Shire v. Watson Federal Circuit precedent; generic

products containing even minor unrecited auxiliary excipients avoid infringement.

● “Comprising” creates an open group permitting additional auxiliary materials, yet still requires

all listed Markush alternatives to satisfy the shared structure/common use test to pass examination.

Applicants cannot switch transitional language mid-prosecution to retroactively expand scope without

new specification support. Third, prosecution history estoppel fully restricts post-grant Markush

enforcement. If an applicant splits, narrows or deletes Markush species to overcome an improper

group rejection during examination, all surrendered alternative chemical classes are permanently

excluded from claim scope in infringement lawsuits. Courts will reference the original office action

rejection and amendment responses to interpret the enforceable boundaries of allowed Markush

limitations. Fourth, indefinite §112(b) rejections apply to overly expansive Markush rosters. Groups

listing thousands of unspecified variable substituents with no disclosed subgenus boundaries are

rejected for indefiniteness, as a PHOSITA cannot reasonably determine the metes and bounds of the

claimed inventionUnited States Patent and Trademark Office. All Markush alternative species must

receive enabling disclosure, working examples and performance data within the original specification to

avoid written description defects. Fifth, provisional election of species is mandatory for contested broad

Markush claims. Examiners may demand applicants select one representative species for prioritized

examination; claims covering non-elected, patentably distinct species are held withdrawn until the core

Markush grouping defects are fully cured via amendmentUnited States Patent and Trademark Office.

Late addition of new Markush species during response constitutes prohibited new matter, barred under

MPEP §608.

Practical Compliance Guidance for Global Chemical & Biotech Enterprises

Draft Markush groups around a single unified core structural scaffold before claim drafting; separate

inorganic, aliphatic, aromatic and heterocyclic raw materials into independent narrow Markush

limitations instead of combining disparate chemical families in one generic grouping. Select

transitional language strategically at initial filing: use “comprising” if auxiliary additives will be

deployed in commercial formulations; reserve “consisting of” only for single-component

controlled-release matrix systems where blend exclusion is commercially critical, and

document the scope intent explicitly in the specification background section. Include multiple

working embodiments covering every primary Markush alternative species in the specification,

with quantitative performance data proving each variant delivers the identical core technical

utility, eliminating written description and improper group rejection risks. Avoid overloaded

open-ended Markush lists with unlimited variable substituents; define clear subgenus cutoffs,

molecular weight ranges and backbone constraints to satisfy §112 definiteness standards

and prevent indefiniteness office actions. Preserve full prosecution history records when

amending Markush groups to overcome examiner rejections; document all surrendered

chemical classes in internal IP risk files to accurately predict future infringement scope limitations

under estoppel rules. Retain U.S. patent counsel specializing in chemical Markush prosecution

to audit generic claim frameworks pre-filing, split defective mixed-class groups into compliant

narrow limitations, and align specification working examples to fully support every listed Markush

alternative.Conclusion

The Markush generic claim framework is indispensable for protecting multi-species chemical,

pharmaceutical and material inventions in the U.S., yet the rigid shared structure/common use test,

transitional phrase scope rules and prosecution history estoppel create severe long-term

enforcement risks for carelessly drafted broad groupings. This Federal Circuit generic drug

infringement reversal fully demonstrates that cutting corners to combine unrelated chemical families

into a single overloaded Markush will trigger examination rejections, force scope-narrowing

amendments, and permanently surrender valuable enforceable claim coverage against competitors.

For cross-border pharma, battery material and specialty chemical R&D teams, narrow single-family

Markush grouping design, intentional transitional wording selection, comprehensive supporting

specification embodiments, and proactive pre-filing claim audit are mandatory to secure fully

allowable, broadly enforceable U.S. generic patent claims.

Hyperlink List：

● USPTO MPEP §2117 Full Official Markush Claim Examination Standards (2024 Update):

https://www.uspto.gov/web/offices/pac/mpep/s2117.html

● USPTO MPEP §803 Provisional Species Election Rules for Broad Markush Claims：

https://www.uspto.gov/web/offices/pac/mpep/s803.html